Why I No Longer Like Polynovo (ASX: PNV) Shares
Polynovo has a great product, but the company has much leadership turmoil for my taste.
Ethical Equities Investing
4 Key Risks Keeping Me Out Of Acusensus Shares (ASX:ACE)
Acusensus (ASX: ACE) is leading road rule enforcement company. The revenue growth is attractive but I hesitate over a few key risks.
Vysarn (ASX: VYS) H1 FY 2025 Results Analysis
Vysarn (ASX: VYS) has a lot of moving parts, and not all are growing.
SiteMinder (ASX: SDR) 1H FY25 Half-Year Results Analysis
The company is still growing revenue but free cash flow generation and profit margins are tracking below expectations.
The Macroeconomic Zeitgeist Is Changing: This Is Your Wake Up Call
Markets have entered “risk off” mode, I think there is good reason for it.
Why I Will Sell My AF Legal Shares (ASX: AFL)
3 reasons I will sell my shares in AF Legal after considering the half-year report.
Dicker Data (ASX: DDR) Shows Green Shoots In 2024 Full Year Results
Dicker Data (ASX: DDR) showed a strong profitability improvement in the second half of its CY 2024 reporting year.
Monash IVF (ASX: MVF): Growth Strategy Shifts In H1 FY 2025 Result
Monash IVF (ASX: MVF) shifts from acquisitions to organic growth, eyeing Victoria’s recovery, global expansion, and cost efficiencies to drive future gains.
Kip McGrath Education Centres (ASX: KME) H1 FY2025 Result: The Good, the Bad and the Tutorfly
The KME H1 FY 2025 results showed modest revenue growth, improved profit, and a strengthening balance sheet.
Polynovo (ASX: PNV) Disappoints Market With H1 FY 2025 results
Doctors love Polynovo’s Novosorb BTM and Novosorb MTX products, but the market hated its H1 FY 2025 results.
IPD Group (ASX: IPG) Reports Impressive H1 FY 2025 Results: But Are There Gremlins Under The Surface?
IPD Group (ASX: IPG) reported decent results and the IPD Group share price has moved up slightly, despite weak commercial construction.
Audinate (ASX: AD8) H1 FY 2025 Results: Has The Worst Passed?
Growth Gauge has long followed Audinate shares, and is expecting more optimism in the future, after the undeniably tough H1 FY 2025 results were released.
BSA Ltd (ASX:BSA) Director Sold Shares Before 80% BSA Share Price Fall
The BSA Ltd share price fell 83% yesterday.
An Introduction To Centrepoint Alliance (ASX: CAF)
Chris Coe explains why he recently bought some share in this little known dividend stock with a P/E ratio around 9.
Fiducian Group (ASX: FID) Reports Solid H1 FY 2025 Results
The Fiducian Group share price gained around 10% in response to some fairly solid H1 FY 2025 results.
Adore Beauty (ASX: ABY) Expands Retail Footprint, But Will It Boost Sales?
Adore Beauty (ASX: ABY) reports strong margin expansion in H1 FY25, but revenue growth remains weak. With 25+ stores planned, can its shift to physical retail drive long-term gains? Read more.
Pro Medicus (ASX: PME) Share Price Down On Fantastic H1 FY 2025 Results
The Pro Medicus (ASX: PME) share price was down slightly in response to the very strong Pro Medicus H1 FY 2025 results.
Prophecy International (ASX: PRO) Touts Itself As “AI Enabler” In “Business Growth Update” Disclosing 1% Revenue Growth
AI and cybersecurity are so hot right now yet this little loss making ASX software stock languishes.
Northern Star (ASX:NST) Half-Year Results: Riding the Gold Wave
Northern Star benefitted from higher gold prices, but free cashflow is restrained by capex requirements.
Bravura Solutions (ASX: BVS) Share Price Up On Increased Guidance And Solid H1 FY 2025 Results
The Bravura Solutions (ASX: BVS) turnaround is complete, and the Bravura share price is up 18% after the H1 FY 2025 results.